Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
HPV-Related Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients
Phase 2 N=62 Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
Human Papilloma Virus Infection · Stage III Squamous Cell Carcinoma of the Oropharynx · Stage IVA Squamous Cell Carcinoma of the Oropharynx
Primary: Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 — 94.5 percentage of participants
Phase 2 N=42 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
Cervical Adenocarcinoma · Cervical Squamous Cell Carcinoma · Human Papillomavirus Infection
Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events
N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
Phase 2 N=35 Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
Head and Neck Cancer · Human Papilloma Virus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 15; 9; 11; 4 Participants
Phase 2 N=45 De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC). — 37 Participants
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Phase 2 N=15 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
Phase 2 N=114 De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…
N/A N=12 Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Human Papillomavirus (HPV)-Related Malignancies · Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants
Phase 2 N=22 Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Event (SAEs) — 6; 15; 2; 0 Participants
Phase 2 N=18 Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
Head and Neck Cancer
Primary: Number of Participants With Progression-free Survival — 17 Participants
Phase 2 N=81 Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Human Papillomavirus Infection · Stage I Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma
Primary: 2-year Loco-regional Tumor Control (LRC) Rate — 100; 93; 96.2 percentage of patients
Phase 2 N=11 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Cancer of Head and Neck · Cancer of Cervix · Cancer of Anus
Primary: Number of Participants With Dose Limiting Toxicity (DLT) [Phase 1b] — 0 Participants
Phase 2 N=35 De-Escalation Therapy for Human Papillomavirus Negative Disease
Human Papilloma Virus · Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck
Primary: Deep Response Rate (DRR) — 16; 19 Participants
Phase 2 N=21 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
N/A N=329 Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
Cervical Cancer
Primary: HPV Identification — 95; 142; 78 biopsies
Phase 2 N=48 E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Papillomavirus Infections · Cervical Intraepithelial Neoplasia · Carcinoma In Situ
Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants
Phase 2 N=195 P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
Phase 2 N=12 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Vaginal Cancer · Cervical Cancer · Anal Cancer
Primary: Maximum Tolerated Dose (MTD) — 2 # of cells x 10^11
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Phase 2 N=60 Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Squamous Cell Carcinoma of Oropharynx
Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants
Phase 1 N=12 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Effects of Immunotherapy · Metastatic/Recurrent Cervical Cancer · Cervical Adenocarcinoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants
Phase 2 N=57 M7824 in Subjects With HPV Associated Malignancies
Human Papilloma Virus · Cervical Cancer · Oropharyngeal Cancer
Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants
N/A N=9 Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma
HEAD & NECK Cancer
Primary: To Explore if Ribavirin Therapy for 2 Weeks Decreases Tumor Expression — 4; 2; 3 Participants
Phase 4 N=56 Postpartum HPV Vaccination
HPV-Related Malignancy
Primary: Patient Indication of Willingness to Accept the Vaccine Based on Survey — 56 Participants
Phase 1 N=24 HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
Human Papillomavirus-Related Carcinoma · Oropharyngeal Cancer
Primary: Maximally Tolerated Dose/Fractionation of Hypofractionated Radiation Therapy — 0 Participants
Phase 2 N=90 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Head and Neck Cancer · Precancerous Condition
Primary: 24-month Progression-free Survival — 64 percentage of participants